|
HS Code |
911994 |
| Product Name | 5-Bromo-3-Trifluoromethyl-1H-Indazole |
| Cas Number | 885273-82-5 |
| Molecular Formula | C8H4BrF3N2 |
| Molecular Weight | 265.03 g/mol |
| Appearance | White to off-white solid |
| Melting Point | 125-130°C |
| Purity | ≥98% |
| Smiles | C1=CC2=C(C(=N1)C(F)(F)F)N=NC2Br |
| Solubility | Soluble in DMSO, DMF; sparingly soluble in water |
As an accredited 5-Bromo-3-Trifluoromethyl-1H-Indazole factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Competitive 5-Bromo-3-Trifluoromethyl-1H-Indazole prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
5-Bromo-3-trifluoromethyl-1H-indazole often draws the attention of researchers who are looking to push the boundaries of pharmaceutical and agrochemical development. I’ve seen it show up in stacks of literature and trade shows, each time as a cornerstone for new research projects or a hard-to-replace tool in med-chem labs. This compound balances a bromine atom and a trifluoromethyl group on a fused indazole ring—a deciding factor for both its chemical behavior and its popularity among process chemists. Bringing these elements together in one molecule adds up to a starting point that gets a lot of interest.
I've watched enough synthetic routes begin and end at the indazole core. The pairing of a bromine at the 5-position, with a trifluoromethyl group at the 3-position, widens the options for downstream chemistry. The bromine acts as a handle for cross-coupling (for those Suzuki or Buchwald-Hartwig fans), while the CF3 group introduces valuable electronegativity. Switching these two groups—either in their placement or in their identity—absolutely changes the story. Anyone who’s tried working with simple indazoles without either a halogen or an electron-withdrawing group knows how uncooperative they can get during stepwise derivatization. With this molecule, that’s less of an issue.
The track record for 5-Bromo-3-trifluoromethyl-1H-indazole hits hardest in medicinal chemistry programs. For those who work in early-stage drug discovery, speed matters, and failures burn time and money fast. The key to its popularity comes from its reactivity and versatility. Chemists lean on the bromine group to open up new rings or tether bioactive side chains, using tried-and-true cross-coupling methodologies. The trifluoromethyl group does double duty—it tunes the molecule’s metabolic stability and adds a bit of insurance against oxidative breakdown. Tweak either group, and you might find your scaffold less potent or more easily metabolized.
Beyond drug work, crop-protection chemists see this compound as a shortcut to heterocyclic scaffolds with improved activity against pests and weeds. You won’t find it replacing core building blocks in every project, but it shows up reliably when both stability and reactivity are in high demand. Compared to unsubstituted indazoles, this version shrugs off nucleophilic attack and resists decomposition, making it a better option in scale-up scenarios.
Not every indazole is equal in the eyes of a process chemist or a synthetic bench worker. The choices boil down to more than purity or price—reactivity and downstream compatibility make or break projects. Compared to counterparts without a CF3 at the 3-position, or those where chlorine stands in for bromine, 5-bromo-3-trifluoromethyl-1H-indazole delivers a cleaner, more predictable coupling profile. This reduces side-product headaches and allows for broader reaction conditions. That unpredictability in less-substituted analogs usually means lost yield and extra purification steps. Labs that run on tight budgets and timelines lean into options that pay off with fewer surprises.
Some competitors swap the trifluoromethyl for a methyl group or a nitro, but these changes ripple through the entire synthesis workflow. For example, a nitro group cranks up electronic activation but often limits compatibility with delicate reaction conditions. Meanwhile, methyl groups don’t have the electron-withdrawing backbone that CF3 brings—synthetic bottlenecks appear, and the end-products’ pharmacology looks different, sometimes less desirable.
Synthetic chemists consider more than what a molecule is—they weigh what it lets them do. On the bench, the bromine substituent on indazole makes palladium-catalyzed chemistry reliable, and repeatable. I've heard from colleagues who tried running similar substitution patterns with iodinated analogs. They tell of quick, but less controllable, reactions. With chlorine, the activation barrier for cross-coupling climbs, and yields tumble. Bromine, in this specific position, finds the Goldilocks zone.
Trifluoromethyl groups parallel a trend seen in several drug approvals and commercial crop protectants. Their inclusion can crank up a molecule's lipophilicity, improve membrane permeability, and block oxidative enzymes from chewing up new molecules before they hit their targets. That’s value you cannot always predict on paper, but countless SAR (structure-activity relationship) campaigns confirm it in the real world—often after scientists put in years of synthetic effort.
Pricing and availability used to be pain points for exotic indazoles, but recent improvements in scale-up manufacturing have shifted that landscape. Producers now offer this compound at a reasonable cost, in both research and bulk grades. I remember a time when single gram lots came by air from overseas specialty shops; now, most chemical distributors stock it, responding to growing demand across medicinal, material, and agricultural chemistry.
Handling is another place where 5-bromo-3-trifluoromethyl-1H-indazole scores points. Unlike similar molecules packed with unstable groups, this one stores well and doesn't foul up analytical columns. Its melting point stays within a practical working range, and the crystalline character makes measurement and weighing accurate. Over the years, these small victories add up, setting it apart from analogs that demand extra caution with light, moisture, or temperature swings.
The drive for fluorinated heterocycles in drug libraries links back to their track record in boosting the metabolic profile of lead molecules. Just look at recent approvals by the FDA—more than half of the small-molecule new drugs feature at least one fluorinated component. The trifluoromethyl group stands out for preserving core activity, even as side chains morph in response to new disease targets.
Research published in Journal of Medicinal Chemistry and Chemical Reviews points to CF3 substitution as a “privileged modification” for enhancing blood-brain barrier penetration and resisting metabolic deactivation. The distinctive edge that 5-bromo-3-trifluoromethyl-1H-indazole brings is clear to anyone running hit-to-lead campaigns in CNS therapeutics or anti-infective programs. You see synthetic failures drop. You see off-target metabolism drop. The cumulative benefit of starting with a scaffold primed for these features ends up cutting weeks out of project timelines.
Not many years ago, this molecule's role in synthesis felt like a niche play. As more case studies landed, and research funding shifted toward efficiency, 5-bromo-3-trifluoromethyl-1H-indazole cemented its credibility. Early adopters lined up in the pharmaceutical industry, where every molecule entering the clinic must tick boxes for metabolic stability and synthetic tractability. Now, you also find chemical vendors supporting panel screens for new anti-microbial agents, pre-built libraries in agrochemical discovery, and more experiments in materials science.
The shift reflects more than convenience. This molecule doesn't try to be everything to everyone, but it stands as a kind of backbone for efforts that can't tolerate wasted time. I've watched teams that used to struggle with late-stage functionalization breathe easier after switching to indazoles sporting both bromine and trifluoromethyl at the right places. It's a choice that reduces troubleshooting and allows for a more focused dive into more novel modifications—where the real intellectual property is born.
No chemical solves all problems. In some catalytic systems, the trifluoromethyl group may compete during cross-coupling or alter selectivity in unexpected ways. I’ve heard complaints that certain palladium sources or ligands work less efficiently here than on simpler analogs. The solution lies in method development and matching the reaction parameters to the substrate—maintaining ligand and base choice open rather than defaulting to what worked “last time.” It pays to run small test reactions during route scouting.
Sourcing, despite improvement, sometimes slows down scale-up. Batch-to-batch consistency across suppliers isn’t always guaranteed, and the bromine position on the indazole can open the door for trace impurities if quality control falls short. Certification and independent analysis fill in this gap. I’ve always encouraged small-scale verification—NMR and HPLC checks—before moving to larger syntheses, especially with new suppliers or changing regulatory lots. Open lines of communication with chemical providers now help researchers address these points up front.
Handling of halogenated and fluorinated products always prompts a few extra questions in safety meetings. While 5-bromo-3-trifluoromethyl-1H-indazole ranks as stable, it’s still part of a chemical family that can present downstream disposal and exposure challenges. Waste streams need attention, and regulatory compliance stays at the forefront of bulk production discussions. In my own work, I’ve seen labs turn to solvent alternatives or engineered capture systems to manage even trace emissions. These steps cut both liability and long-term cost.
Some research circles press for greener synthesis of indazoles—fewer steps, safer reagents, and renewable starting materials. As new synthetic routes appear in journals, the best commercial producers update their protocols. The large number of academic groups chasing more benign indazole synthesis shows that the field recognizes this need. Implementation takes time, especially amid tight margins and regulatory barriers, but momentum favors continued improvement in both process efficiency and source material sustainability.
Success in chemistry rarely traces to a single product, but certain compounds—like 5-bromo-3-trifluoromethyl-1H-indazole—occupy unique territory. It’s more than just useful; it actively removes barriers in modern synthesis. Over the last decade of watching chemical supply chains and research priorities shift, I've found that products which save time, trim unnecessary risk, or allow exploration of new chemical space earn their keep.
For newer researchers or those building out pilot-scale synthetic readiness, the value ties to predictability. With this indazole, the knowns outweigh the unknowns. Consistent purity profiles, manageable storage and shipment, and a deep reservoir of supporting literature combine to justify its continued use. These track records breed confidence among teams building both research and commercial pipelines. The ability to spend less energy troubleshooting—saving both labor and material—makes the investment worthwhile even before considering regulatory or environmental factors.
The pharmaceutical industry’s embrace of this indazole isn’t just anecdotal. Patent landscaping and hit generation programs document its application across kinase inhibitors, antiviral projects, and inflammation targets. When I look at how often it pops up in primary screening hits, I see a pattern: synthetic teams trust it to open up series that other indazoles shut down. Even in more mainstream chemical manufacturing, where costs rule decision-making, it remains in rotation when yield and purity demand a higher standard.
Agricultural chemistry’s adoption is noteworthy for a different reason. Under stricter regulations for environmental persistence, the balance between reactivity and stability draws clear lines between promising and problematic molecules. Products that fail to degrade at a controlled rate, or that escape into nearby water, end up on restricted lists. The trifluoromethyl group’s influence isn’t a blanket solution, but when thoughtfully included—supported by solid fate and transport data—it extends product lifespans while keeping breakdown profiles inside desired boundaries.
Materials science makes use of the unique electronic properties this compound delivers. Organic electronics, for instance, leverage the bromine-CF3 scaffold to tune bandgaps and modulate charge transport. The presence of stable, electron-withdrawing substituents can nudge device performance forward in a way unmodified indazoles struggle to replicate. Colleagues working on OLED and organic solar projects cite its use as a building block that “moves the needle” in early-stage experiments.
Chemistry never stands still. Every few years, new reagents promise easier synthesis, higher reactivity, or lower cost. In my experience, those whose value extends across multiple applications tend to outlast trends or hype cycles. 5-bromo-3-trifluoromethyl-1H-indazole remains one of those workhorses, bridging gaps between tricky early-stage med-chem screens and the rigors of process optimization. It will not supplant every other indazole in today’s catalogs, yet it continues to show up in the hands of smart, forward-looking chemists.
Choosing it over lookalike molecules boils down to experience and expectation. If a project’s workflow pressures chemists to reduce iteration cycles, avoid cleanup headaches, and protect sensitive functionality, this molecule holds a natural edge. As new analytical techniques and synthetic tools appear, I expect the ways chemists use this scaffold will expand—not just out of tradition, but because it delivers concrete, memorable improvements in daily lab practice.
Proactive planning ahead of synthesis pays dividends. Ensuring a steady supply chain, confirming compatibility with the most common ligands and solvents, and benchmarking small-scale reactions before going full tilt all rank as practices I've seen separate successful teams from those stuck firefighting. Juggling workload, limited resources, and pressure to deliver new chemical space, teams who circle back to proven tools like 5-bromo-3-trifluoromethyl-1H-indazole almost always outpace those locked into less promising chemistry.
Sharing notes between groups and leveraging published data smooth the way for newcomers and established labs alike. Journals, patents, technical notes—all of these feed into a growing reservoir that supports smarter choices. As regulatory expectations become more precise, and as competition to deliver new value rises, choosing stable, well-characterized reagents only gets more important.
5-Bromo-3-trifluoromethyl-1H-indazole stands out not by accident, but because the sum of its features lines up with the real demands of modern chemistry. It answers calls for reliability, smart reactivity, and a safety profile appropriate for both research and large-scale production. Its role, earned through years of bench experience and industry feedback, reflects a shift toward tools that help, not hinder, innovation. As new challenges arise and chemists stretch further into new applications, willingness to lean on compounds with a proven record can be the difference between a project that drags and one that delivers.